recombinant anti-CD3 humanized mAb (Shanghai Zhangjiang Biotechnology)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namerecombinant anti-CD3 humanized mAb (Shanghai Zhangjiang Biotechnology)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitors
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsRejection of organ transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Zhangjiang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Zhangjiang Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantation

Other Information

ATC CodeN/A
Related LinksN/A